Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Alnylam Pharmaceuticals

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities7.10%
Size of stake in company0.30%
Market capitalizationUSD 59.7 bn

Sector

RNAi

Main candidate

Vutrisiran

Main indications

ATTR Amyloidosis

About the company

Alnylam is a biotechnology company focused on developing RNA therapies, a treatment approach to selectively block the synthesis of specific disease-causing proteins. The company is focusing on four therapeutic areas including genetic medicines, cardio-metabolic diseases, infectious diseases, central nervous system diseases and ocular diseases. Alnylam company was founded in 2002 and headquartered in Cambridge, Massachusetts, in the US. Alongside Ionis, another of BB Biotech´s portfolio companies, Alnylam is considered one of the leaders in the RNA interference field. The company has four products approved and on the market: Patisiran, Givosiran, Lumasiran and Vutrisiran.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.